Stoke Therapeutics, Inc. (STOK)Healthcare | Biotechnology | Bedford, United States | NasdaqGS
31.62 USD
-0.97
(-2.976%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 31.62 |
Hot Take ↕ | Aug. 22, 2026, 1:05 a.m. EDT
The investment thesis here hinges entirely on the binary outcome of the Dravet syndrome lead asset entering its final stretch, a narrative reinforced by Goldman Sachs initiating a buy rating. Fundamentally, the company remains a classic biotech gamble: it is burning cash with negative revenue growth and no dividend to speak of, trading at a premium valuation despite a history of severe volatility including a 67% crash in 2023. However, the market has seemingly priced in a recovery, with the stock rallying 143% in 2024 and 42% in 2025, suggesting investors believe the pipeline can turn the corner. The options market confirms this bullish bias, with heavy call buying targeting a $40 price level within months. While the statistical forecast models see no immediate edge due to the asset's noisy price history, the confluence of a 'strong buy' analyst consensus, a catalyst-rich event calendar, and aggressive speculative positioning suggests a high-risk, high-reward setup where the next few months could define whether this is a turnaround story or a value trap. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.042051 |
| AutoETS | 0.042052 |
| AutoTheta | 0.043319 |
| MSTL | 0.053962 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 38% |
| H-stat | 2.26 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.223 |
| Excess Kurtosis | -1.10 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.776 |
| Revenue per Share | 0.442 |
| Market Cap | 2,040,319,744 |
| Forward P/E | -9.00 |
| Beta | 1.23 |
| Website | https://www.stoketherapeutics.com |
As of Aug. 22, 2026, 1:05 a.m. EDT: Speculators are positioning for a significant upside move, evidenced by massive open interest and volume in $40 calls expiring in November, which represents a 24% gain from current prices. Conversely, put writers are heavily exposed at lower strikes ($20-$25), creating a 'pin risk' zone where a drop to these levels would trigger a cascade of buying. The implied volatility skew shows elevated fear at the money for near-term expiration, but the structural positioning favors a rally toward the $40 strike.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.6140888 |
| Address1 | 45 Wiggins Avenue |
| All Time High | 71.58 |
| All Time Low | 3.35 |
| Ask | 40.44 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 939,100 |
| Average Daily Volume3 Month | 860,003 |
| Average Volume | 860,003 |
| Average Volume10Days | 939,100 |
| Beta | 1.228 |
| Bid | 31.62 |
| Bid Size | 1 |
| Board Risk | 6 |
| Book Value | 5.537 |
| City | Bedford |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 31.62 |
| Current Ratio | 7.692 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 32.55 |
| Day Low | 31.49 |
| Debt To Equity | 0.776 |
| Display Name | Stoke Therapeutics |
| Earnings Call Timestamp End | 1,785,787,200 |
| Earnings Call Timestamp Start | 1,785,787,200 |
| Earnings Timestamp | 1,785,787,200 |
| Earnings Timestamp End | 1,793,736,000 |
| Earnings Timestamp Start | 1,793,736,000 |
| Ebitda | -221,632,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -7.897 |
| Enterprise To Revenue | 63.44 |
| Enterprise Value | 1,750,183,808 |
| Eps Current Year | -3.62068 |
| Eps Forward | -3.51512 |
| Eps Trailing Twelve Months | -3.29 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 31.189 |
| Fifty Day Average Change | 0.43100166 |
| Fifty Day Average Change Percent | 0.013819029 |
| Fifty Two Week Change Percent | 61.40888 |
| Fifty Two Week High | 40.22 |
| Fifty Two Week High Change | -8.6 |
| Fifty Two Week High Change Percent | -0.21382397 |
| Fifty Two Week Low | 18.8 |
| Fifty Two Week Low Change | 12.820002 |
| Fifty Two Week Low Change Percent | 0.681915 |
| Fifty Two Week Range | 18.8 - 40.22 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,560,951,000,000 |
| Float Shares | 49,216,101 |
| Forward Eps | -3.51512 |
| Forward P E | -8.995425 |
| Free Cashflow | -106,202,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 170 |
| Fullday Change | -0.969999 |
| Fullday Change Percent | -2.97637 |
| Fullday Price | 31.62 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 1.0 |
| Gross Profits | 27,588,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.036930002 |
| Held Percent Institutions | 1.23621 |
| Implied Shares Outstanding | 64,526,242 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. |
| Long Name | Stoke Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 2,040,319,744 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_251758622 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -207,903,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,102,910,226 |
| Number Of Analyst Opinions | 13 |
| Open | 32.2 |
| Operating Cashflow | -177,987,008 |
| Operating Margins | -7.01651 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 781 430 8200 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 31.62 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 32.59 |
| Price Eps Current Year | -8.733166 |
| Price Hint | 2 |
| Price To Book | 5.710674 |
| Price To Sales Trailing12 Months | 73.95679 |
| Profit Margins | 0.0 |
| Quick Ratio | 7.191 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.14286 |
| Region | US |
| Regular Market Change | -0.969999 |
| Regular Market Change Percent | -2.97637 |
| Regular Market Day High | 32.55 |
| Regular Market Day Low | 31.49 |
| Regular Market Day Range | 31.49 - 32.55 |
| Regular Market Open | 32.2 |
| Regular Market Previous Close | 32.59 |
| Regular Market Price | 31.62 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 754,095 |
| Return On Assets | -0.35868 |
| Return On Equity | -0.61104 |
| Revenue Growth | -0.325 |
| Revenue Per Share | 0.442 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 64,526,242 |
| Shares Percent Shares Out | 0.2011 |
| Shares Short | 12,978,102 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 15,692,610 |
| Short Name | Stoke Therapeutics, Inc. |
| Short Percent Of Float | 0.20889999 |
| Short Ratio | 16.88 |
| Source Interval | 15 |
| State | MA |
| Symbol | STOK |
| Target High Price | 60.0 |
| Target Low Price | 35.0 |
| Target Mean Price | 46.46154 |
| Target Median Price | 44.0 |
| Total Cash | 292,817,984 |
| Total Cash Per Share | 4.538 |
| Total Debt | 2,682,000 |
| Total Revenue | 27,588,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.29 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 31.849325 |
| Two Hundred Day Average Change | -0.22932434 |
| Two Hundred Day Average Change Percent | -0.007200289 |
| Type Disp | Equity |
| Volume | 754,095 |
| Website | https://www.stoketherapeutics.com |
| Zip | 1,730 |